Assessment of Liver Fibrosis In Non-Alcoholic Fatty Liver Disease Using Real-Time Elastography

Abdu, Sabry; Abdulaziz, Badawy A.; kharbotly, Enas El-; Nassief, Anwar

doi:10.21608/bmfj.2020.120188

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In NAFLD‐related fibrosis, occurrence and progression is the most critical event in the natural history of this disease. 10 , 11 Recognition of the NAFLD cohort which is more susceptible for fibrosis progression is still an unmet need. ABCA1 genotypes were found to be strongly related to lipid metabolism and hepatic enzymology in NAFLD.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients

Ghanem

Elsabaawy

Abdelkareem

et al. 2022

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

Introduction It had been evident that non‐alcoholic fatty liver disease (NAFLD) is the new era epidemic. Despite emergence of many drugs on the pipeline that considered candidates to cure NAFLD/NASH, the critical need for defining the cohort liable to fibrosis progression is yet unmet. Aim Evaluate ABCA1 (rs1800977) genotyping as a noninvasive predictor of liver fibrosis severity. Materials and Methods This study included 118 liver biopsy‐proven NAFLD‐patients. According to Metavir‐fibrosis‐staging, cases were divided to early fibrosis (74 cases), and 44 cases with significant fibrosis (>F2), added to 49 healthy control subjects. All patients were subjected to liver function tests, lipids profile, triglyceride TG index, and hepatic steatosis index (HSI) and real‐time PCR ABCA1 SNP (rs1800977). Results Significant differences in transaminases (p > .05), albumin (p < .009), cholesterol (p0.03), low density lipoproteins (LDL) (0.006), triglycerides (p < .001), HSI (p < .001), FIB4 (p < .001) and APRI (p < .001) were reported in those with significant than early fibrosis and control groups. CC was the most prevalent in significant (36.4%) than early fibrosis (13.5%) and control groups (8.2%), with prevalence of C allele in significant fibrosis (p ≤ .003). Univariate analysis revealed that DM (p ≤ .001), TG index (p ≤ .022), cholesterol (p ≤ .03), HSI (p ≤ .006), LDL (p ≤ .02), HDL (p ≤ .01), APRI (p ≤ .02) and CC genotype (p ≤ .005) were the main factors affecting fibrosis progression in NAFLD. However multivariate analysis proved only the role of HSI (p ≤ .005), LDL (p ≤ .02), HDL (p ≤ .003) and CC genotype (p ≤ .03) in predicting fibrosis severity. Conclusion Dyslipidemias, hepatic steatosis index and ABCA1 (rs1800977) gene polymorphism CC genotype; were the only independent predictors of advanced fibrosis in NAFLD‐patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients

Ghanem

Elsabaawy

Abdelkareem

et al. 2022

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

show abstract

“…Ultrasonography, conducted by skilled examiners, was used to identify NAFLD. Besides, the NAFLD fibrosis score [7] and FIB-4 score [7] were used for the categorization of the severity of NAFLD.…”

Section: Methodsmentioning

confidence: 99%

Complement C3 as a potential NAFLD predictor in an Egyptian cohort with diabetes and/or obesity

et al. 2022

View full text Add to dashboard Cite

Complement system is becoming increasingly recognized as being intimately tied to obesity and other various metabolic abnormalities linked to it and may be involved in NAFLD. The goal of this study was to see if complement C3 might be used as a diagnostic and prognostic marker in NAFLD patients. Forty-one NAFLD patients and fourteen age- and gender-matched control individuals were enrolled in this study. All subjects were subjected to abdominal ultrasound examination and clinical assessment with special emphasis on the liver function enzymes, blood glucose levels, lipid profile, and kidney function tests. Non-invasive assessment of hepatic steatosis and fibrosis has evolved using serology-based scoring systems such as the Fibrosis-4 score and NAFLD Fibrosis Score (NFS). Additionally, serum levels of complement C3 were determined by the ELISA method. In this study, BMI, cholesterol, triglyceride levels, and NFS were all substantially higher in NAFLD patients compared to healthy controls. Moreover, complement C3 was considerably higher in NAFLD cases (1.52±0.29 g/L) vs. healthy controls (0.93±0.289 g/L) (p<0.001). Compared to lean people (0.93±0.29 g/L), the mean complement C3 levels were significantly higher in obese diabetes (1.69±0.29 g/L), obese non-diabetic (1.48±0.174 g/L), and diabetic non-obese patients (1.36±0.28 g/L). Using a cutoff for complement C3 1.135 (g/L) for distinguishing NAFLD patients from healthy controls has a sensitivity of 90.2% and specificity of 78.6%. In conclusion, serum complement C3 may be useful in the identification of fibrosis in non-alcoholic fatty liver disease. Moreover, complement C3 may be a promising tool for predicting the worsening of liver inflammation.

show abstract

Assessment of Liver Fibrosis In Non-Alcoholic Fatty Liver Disease Using Real-Time Elastography

Cited by 2 publications

References 6 publications

Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients

Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients

Complement C3 as a potential NAFLD predictor in an Egyptian cohort with diabetes and/or obesity

Contact Info

Product

Resources

About